Results 141 to 150 of about 18,827 (200)

Targeting CDK4/6 in Combination with Phage-Based Anti-HER2 Vaccination Overcomes Immune Evasion and Enhances the Anticancer Response in Breast Cancer. [PDF]

Pharmaceutics
Wang J, Lamolinara A, Tomassoni D, Conti L, Cossu C, Di Lorenzo A, Giangrossi M, Lufrano D, Vaithianathan V, Orlando F, Olivieri F, Marcozzi S, Beghelli D, Belletti B, Amici A, Falconi M, Cavallo F, Iezzi M, Marchini C.   +18 more
europepmc   +1 more source

Gastrointestinal toxicity associated with cyclin-dependent kinase 4/6 inhibitors in breast cancer patients: insights from a real-world pharmacovigilance analysis. [PDF]

Front Med (Lausanne)
Lu M, Yuan L, Liu J, Dou Y, Cui J.
europepmc   +1 more source

ESR1 mutations and CDK4/6 inhibitor choice shape clonal selection and adaptive cell states during acquired resistance. [PDF]

Genome Med
Guarducci C, Abravanel D, Russo D, Prasad K, Fu J, Nagy Z, Rao V, Nardone A, Kuang Y, Feit A, Ma W, Feit GC, Hermida-Prado F, Heraud C, Munoz Gomez M, Garcia Cortes DE, Kurnia P, Gomez Tejeda Zanudo J, Li R, Qiu X, Cristea S, Feiglin A, Cheng YC, Lin NU, Tolaney SM, Malorni L, Sicinski P, Polyak K, Paweletz C, Long H, Stewart C, Michor F, Getz G, Brown M, Jeselsohn R.   +34 more
europepmc   +1 more source

Evolving First-Line Endocrine Therapy in HR+/HER2- Metastatic Breast Cancer: CDK4/6 Inhibition, Biomarker-Guided Strategies and Emerging Therapeutic Paradigms. [PDF]

Curr Oncol
Abdel-Razeq H, Sharaf B.
europepmc   +1 more source

Immune-Mediated Hepatotoxicity Associated With Ribociclib: A Multipatient Case Series and Management Strategy. [PDF]

Case Rep Oncol Med
Buchalter J, O Donovan H, Jordan E, Galvin Z, Walshe JM.   +4 more
europepmc   +1 more source

Cyclin-dependent kinase 4 and 6 inhibitors and the breast cancer immune ecosystem: immune remodeling, resistance, and therapeutic reprogramming. [PDF]

Front Immunol
Tang Y, Zhu Y, Liu S, Han X, Zhang H, Zhao W.   +5 more
europepmc   +1 more source

Post-CDK4/6 inhibitor therapy in HR+/HER2- advanced breast cancer: expanding options and persisting uncertainties. [PDF]

Explor Target Antitumor Ther
Hollinger AM, Bill R.
europepmc   +1 more source

MKRN2-Mediated Degradation of IGF2BP3 Suppresses MYC and Enhances CDK4/6 Inhibitor Sensitivity in Bladder Cancer. [PDF]

Cancers (Basel)
Pan Q, Shi Q, Zhao Y, Yu T, Bai S, Zhu H, Zhang W, Li Y, Liu Z, Li H, Wang Z, Tong Z.   +11 more
europepmc   +1 more source

Age, Age-Related Comorbidities and Survival in Palbociclib, Ribociclib and Abemaciclib Users With Advanced Breast Cancer: A Nation-Wide Retrospective Cohort Study. [PDF]

Pharmacoepidemiol Drug Saf
Rajamaki B, Tenhunen O, Pylkkänen L, Vo T, Paakinaho A, Turpeinen M, Hartikainen S, Tolppanen AM.   +7 more
europepmc   +1 more source

CDK4/6 inhibitors as conditional immune-priming agents in breast cancer: therapeutic windows, sequencing strategies, and rational combinations with immunotherapy, radiotherapy, and antibody-drug conjugates. [PDF]

Front Immunol
Zheng C, Pan Y, Zheng D, Pan Y.
europepmc   +1 more source